Radiochemical aspects of alpha emitting radionuclides for medical application

References

1. Huclier-Markai, S., Alliot, C., Varmenot, N., Cutler, C. S., Barbet, J.: Alpha-emitters for immuno-therapy: a review of recent developments from chemistry to clinics. Curr. Top. Med. Chem. 23, 2642 (2012).10.2174/1568026611212230002Suche in Google Scholar PubMed

2. McDevitt, M. R., Sgouros, G., Sofou, S.: Targeted and nontargeted α-particle therapies. Annu. Rev. Biomed. Eng. 20, 73 (2018).10.1146/annurev-bioeng-062117-120931Suche in Google Scholar PubMed PubMed Central

3. Lacoeuille, F., Arlicot, N., Faivre-Chauvet, A.: Targeted alpha and beta radiotherapy: an overview of radiopharmaceutical and clinical aspects. Med. Nucl. 42, 32 (2018).10.1016/j.mednuc.2017.12.002Suche in Google Scholar

4. Makvandi, M., Dupis, E., Engle, J. W., Nortier, F. M., Fassbender, M. E., Simon, S., Birnbaum, E. R., Atcher, R. W., John, K. D., Rixe, O., Norenberg, J. P.: Alpha-emitters and targeted alpha therapy in oncology: from basic science to clinical investigations. Target. Oncol. 13, 189 (2018).10.1007/s11523-018-0550-9Suche in Google Scholar PubMed

5. Marcu, L., Bezak, E., Allen, B. J.: Global comparison of targeted alpha vs targeted beta therapy for cancer: in vitro, in vivo and clinical trials. Crit. Rev. Oncol. Hemat. 123, 7 (2018).10.1016/j.critrevonc.2018.01.001Suche in Google Scholar PubMed

6. Cornelissen, B., Vallis, K. A.: Targeting the nucleus: an overview of auger-electron radionuclide therapy. Curr. Drug Discov. Technol. 7, 263 (2010).10.2174/157016310793360657Suche in Google Scholar PubMed

7. Larson, S. M., Carrasquillo, J. A., Cheung, N.-K. V., Press, O. W.: Radioimmunotherapy of human tumours. Nat. Rev. Cancer 15, 347 (2015).10.1038/nrc3925Suche in Google Scholar PubMed PubMed Central

8. Jurcic, J. G., et al.: Targeted α particle immunotherapy for myeloid leukemia. Blood 100, 1233 (2002).10.1182/blood.V100.4.1233.h81602001233_1233_1239Suche in Google Scholar

9. Poty, S., Francesconi, L. C., McDevitt, M. R., Morris, M. J., Lewis, J. S.: α-Emitters for radiotherapy: from basic radiochemistry to clinical studies – part 2. J. Nucl. Med. 59, 1020 (2018).10.2967/jnumed.117.204651Suche in Google Scholar PubMed PubMed Central

10. Martins, C. D., Kramer-Marek, G., Oyen, W. J. G.: Radioimmunotherapy for delivery of cytotoxic radioisotopes: current status and challenges. Expert Opin. Drug Deliv. 15, 185 (2018).10.1080/17425247.2018.1378180Suche in Google Scholar PubMed

11. Kozempel, J., Mokhodoeva, O., Vlk, M.: Progress in targeted alpha-particle therapy. what we learned about recoils release from in vivo generators. Molecules 23, 581 (2018).10.3390/molecules23030581Suche in Google Scholar PubMed PubMed Central

12. Wadas, T. J., Pandya, D. N., Solingapuram Sai, K. K., Mintz, A.: Molecular targeted alpha-particle therapy for oncologic applications. AJR Am. J. Roentgenol. 203, 253 (2014).10.2214/AJR.14.12554Suche in Google Scholar PubMed PubMed Central

13. Elgqvist, J., Frost, S., Pouget, J. P., Albertsson, P.: The potential and hurdles of targeted alpha therapy – clinical trials and beyond. Front. Oncol. 3, 324/1 (2014).10.3389/fonc.2013.00324Suche in Google Scholar PubMed PubMed Central

14. Wilbur, D. S.: Chemical and radiochemical considerations in radiolabeling with α-emitting radionuclides. Curr. Radiopharm. 4, 214 (2011).10.2174/1874471011104030214Suche in Google Scholar PubMed

15. Birnbaum, E. R., Fassbender, M. E., Ferrier, M. G., John, K. D., Mastren, T.: Actinides in Medicine, Encyclopedia of Inorganic and Bioinorganic Chemistry, John Wiley & Sons, Ltd. (2018), p. 1.10.1002/9781119951438.eibc2563Suche in Google Scholar

16. Baum, R. P.: Therapeutic Nuclear Medicine (2014), Springer, Berlin, Heidelberg.10.1007/978-3-540-36719-2Suche in Google Scholar

17. Guseva, L. I.: Radioisotope generators of short-lived α-emitting radionuclides promising for use in nuclear medicine. Radiochemistry 56, 451 (2014).10.1134/S1066362214050014Suche in Google Scholar

18. Price, E. W., Orvig, C.: Matching chelators to radiometals for radiopharmaceuticals. Chem. Soc. Rev. 43, 260 (2014).10.1039/C3CS60304KSuche in Google Scholar PubMed

19. Brechbiel, M. W.: Bifunctional chelates for metal nuclides. Q. J. Nucl. Med. Mol. Imaging 52, 166 (2008).Suche in Google Scholar

20. Tornesello, A. L., Buonaguro, L., Tornesello, M. L., Buonaguro, F. M.: New insights in the design of bioactive peptides and chelating agents for imaging and therapy in oncology. Molecules 22, 1282_1 (2017).10.3390/molecules22081282Suche in Google Scholar PubMed PubMed Central

21. Cutler, C. S., Hennkens, H. M., Sisay, N., Huclier-Markai, S., Jurisson, S. S.: Radiometals for combined imaging and therapy. Chem. Rev. 113, 858 (2013).10.1021/cr3003104Suche in Google Scholar PubMed

22. Jamous, M., Haberkorn, U., Mier, W.: Synthesis of peptide radiopharmaceuticals for the therapy and diagnosis of tumor diseases. Molecules 18, 3379 (2013).10.3390/molecules18033379Suche in Google Scholar PubMed PubMed Central

23. Dekempeneer, Y., Keyaerts, M., Krasniqi, A., Puttemans, J., Muyldermans, S., Lahoutte, T., D’Huyvetter, M., Devoogdt, N.: Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle. Expert Opin. Biol. Ther. 16, 1035 (2016).10.1080/14712598.2016.1185412Suche in Google Scholar PubMed PubMed Central

24. Liko, F., Hindre, F., Fernandez-Megia, E.: Dendrimers as innovative radiopharmaceuticals in cancer radionanotherapy. Biomacromolecules 17, 3103 (2016).10.1021/acs.biomac.6b00929Suche in Google Scholar PubMed

25. National Nuclear Data Center. Brookhaven National Laboratory, 1994.Suche in Google Scholar

26. Meyer, G. J.: Astatine. J. Labelled Comp. Radiopharm. 61, 154 (2018).10.1002/jlcr.3573Suche in Google Scholar PubMed

27. Lahiri, S., Maiti, M.: Recent developments in nuclear data measurements and chemical separation methods in accelerator production of astatine and technetium radionuclides. Radiochim. Acta 100, 85 (2012).10.1524/ract.2011.1888Suche in Google Scholar

28. Hermanne, A., Tárkányi, F., Takács, S., Szücs, Z., Shubin, Y. N., Dityuk, A. I.: Experimental study of the cross-sections of alpha-particle induced reactions on ²⁰⁹Bi. Appl. Radiat. Isotopes 63, 1 (2005).10.1016/j.apradiso.2005.01.015Suche in Google Scholar PubMed

29. Zalutsky, M. R., Pruszynski, M.: Astatine-211: production and availability. Curr. Radiopharm. 4, 177 (2011).10.2174/1874471011104030177Suche in Google Scholar PubMed PubMed Central

30. Guérard, F., Gestin, J. F., Brechbiel, M. W.: Production of [²¹¹At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy. Cancer Biother. Radiopharm. 28, 1 (2013).10.1089/cbr.2012.1292Suche in Google Scholar PubMed PubMed Central

31. Gagnon, K., Risler, R., Pal, S., Hamlin, D., Orzechowski, J., Pavan, R., Zeisler, S., Wilbur, D. S.: Design and evaluation of an external high-current target for production of ²¹¹At. J. Labelled Comp. Radiopharm. 55, 436 (2012).10.1002/jlcr.2968Suche in Google Scholar

32. Qaim, S. M., Stöcklin, G.: Production of some medically important short-lived neutron-deficient radioisotopes of halogens. Radiochim. Acta 34, 25 (1983).10.1524/ract.1983.34.12.25Suche in Google Scholar

33. Crawford, J. R., Kunz, P., Yang, H., Schaffer, P., Ruth, T. J.: ²¹¹Rn/²¹¹At and ²⁰⁹At production with intense mass separated Fr ion beams for preclinical ²¹¹At-based α-therapy research. Appl. Radiat. Isotopes 122, 222 (2017).10.1016/j.apradiso.2017.01.035Suche in Google Scholar PubMed

34. Lindegren, S., Bäck, T., Jensen, H. J.: Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields. Appl. Radiat. Isotopes 55, 157 (2001).10.1016/S0969-8043(01)00044-6Suche in Google Scholar

35. Aneheim, E., Albertsson, P., Bäck, T., Jensen, H., Palm, S., Lindegren, S.: Automated astatination of biomolecules – a stepping stone towards multicenter clinical trials. Sci. Rep. 5, 12025_1 (2015).10.1038/srep12025Suche in Google Scholar PubMed PubMed Central

36. O’Hara, M. J., Krzysko, A. J., Niver, C. M., Morrison, S. S., Owsley, S. L., Jr., Hamlin, D. K., Dorman, E. F., Scott Wilbur, D.: An automated flow system incorporating in-line acid dissolution of bismuth metal from a cyclotron irradiated target assembly for use in the isolation of astatine-211. Appl. Radiat. Isotopes 122, 202 (2017).10.1016/j.apradiso.2017.02.001Suche in Google Scholar PubMed

37. Balkin, E. R., Hamlin, D. K., Gagnon, K., Chyan, M.-K., Pal, S., Watanabe, S., Wilbur, D. S.: Evaluation of a wet chemistry method for isolation of cyclotron produced [²¹¹At]astatine. Appl. Sci. 3, 636 (2013).10.3390/app3030636Suche in Google Scholar

38. Zalutsky, M., Vaidyanathan, G.: Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. Curr. Pharm. Des. 6, 1433 (2000).10.2174/1381612003399275Suche in Google Scholar PubMed

39. Wilbur, D. S.: [²¹¹At]Astatine-labeled compound stability: issues with released [²¹¹At]astatide and development of labeling reagents to increase stability. Curr. Radiopharm. 1, 144 (2008).10.2174/1874471010801030144Suche in Google Scholar

40. Couturier, O., Supiot, S., Degraef-Mougin, M., Faivre-Chauvet, A., Carlier, T., Chatal, J. F., Davodeau, F., Cherel, M.: Cancer radioimmunotherapy with alpha-emitting nuclides. Eur. J. Nucl. Med. Mol. I. 32, 601 (2005).10.1007/s00259-005-1803-2Suche in Google Scholar PubMed

41. Wilbur, D. S., Hadley, S. W., Hylarides, M. D., Abrams, P. G., Beaumier, P. A., Morgan, A. C., Reno, J. M., Fritzberg, A. R.: Development of a stable radioiodinating reagent to label monoclonal antibodies for radiotherapy of cancer. J. Nucl. Med. 30, 216 (1989).Suche in Google Scholar

42. Wilbur, D. S.: Radiohalogenation of proteins: an overview of radionuclides, labeling methods, and reagents for conjugate labeling. Bioconj. Chem. 3, 433 (1992).10.1021/bc00018a001Suche in Google Scholar PubMed

43. Zalutsky, M. R., Bigner, D. D.: Radioimmunotherapy with α-particle emitting radioimmunoconjugates. Acta Oncol. 35, 373 (1996).10.3109/02841869609101654Suche in Google Scholar PubMed

44. Wilbur, D. S., Chyan, M. K., Nakamae, H., Chen, Y., Hamlin, D. K., Santos, E. B., Kornblit, B. T., Sandmaier, B. M.: Reagents for astatination of biomolecules. 6. An intact antibody conjugated with a maleimido-closo-decaborate(2-) reagent via sulfhydryl groups had considerably higher kidney concentrations than the same antibody conjugated with an isothiocyanato-closo-decaborate(2-) reagent via lysine amines. Bioconj. Chem. 23, 409 (2012).10.1021/bc200401bSuche in Google Scholar PubMed PubMed Central

45. Zalutsky, M. R., Reardon, D. A., Akabani, G., Coleman, R. E., Friedman, A. H., Friedman, H. S., McLendon, R. E., Wong, T. Z., Bigner, D. D.: Clinical experience with alpha-particle emitting ²¹¹At: treatment of recurrent brain tumor patients with ²¹¹At-labeled chimeric antitenascin monoclonal antibody 81C6. J. Nucl. Med. 49, 30 (2008).10.2967/jnumed.107.046938Suche in Google Scholar

46. Cederkrantz, E., Andersson, H., Bernhardt, P., Bäck, T., Hultborn, R., Jacobsson, L., Jensen, H., Lindegren, S., Ljungberg, M., Magnander, T., Palm, S., Albertsson, P.: Absorbed doses and risk estimates of ²¹¹At-MX35 F(ab′)₂ in intraperitoneal therapy of ovarian cancer patients. Int. J. Radiat. Oncol. 93, 569 (2015).10.1016/j.ijrobp.2015.07.005Suche in Google Scholar

47. Reardon, D. A., Zalutsky, M. R., Bigner, D. D.: Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Rev. Anticancer 7, 675 (2007).10.1586/14737140.7.5.675Suche in Google Scholar

48. Andersson, H., Cederkrantz, E., Bäck, T., Divgi, C., Elgqvist, J., Himmelman, J., Horvath, G., Jacobsson, L., Jensen, H., Lindegren, S., Palm, S., Hultborn, R.: Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of ²¹¹At-MX35 F(ab′)₂ – a phase I study. J. Nucl. Med. 50, 1153 (2009).10.2967/jnumed.109.062604Suche in Google Scholar

49. Li, Y., Hamlin, D. K., Chyan, M. K., Wong, R., Dorman, E. F., Emery, R. C., Woodle, D. R., Manger, R. L., Nartea, M., Kenoyer, A. L., Orozco, J. J., Green, D. J., Press, O. W., Storb, R., Sandmaier, B. M., Wilbur, D. S.: cGMP production of astatine-211-labeled anti-CD45 antibodies for use in allogeneic hematopoietic cell transplantation for treatment of advanced hematopoietic malignancies. PLoS One 13, e0205135 (2018).10.1371/journal.pone.0205135Suche in Google Scholar

50. Atcher, R. W., Friedman, A. M., Hines, J. J.: An improved generator for the production of ²¹²Pb and ²¹²Bi from ²²⁴Ra. Appl. Radiat. Isotopes 39, 283 (1988).10.1016/0883-2889(88)90016-0Suche in Google Scholar

51. Hassfjell, S. P.: A ²¹²Pb generator based on a ²²⁸Th source. Appl. Radiat. Isotopes 55, 433 (2001).10.1016/S0969-8043(00)00372-9Suche in Google Scholar

52. Mirzadeh, S.: Generator-produced alpha-emitters. Appl. Radiat. Isotopes 49, 345 (1998).10.1016/S0969-8043(97)00175-9Suche in Google Scholar

53. Westrom, S., Generalov, R., Bonsdorff, T. B., Larsen, R. H.: Preparation of ²¹²Pb-labeled monoclonal antibody using a novel ²²⁴Ra-based generator solution. Nucl. Med. Biol. 51, 1 (2017).10.1016/j.nucmedbio.2017.04.005Suche in Google Scholar PubMed

54. Despotopulos, J. D., Kmak, K. N., Moody, K. J., Shaughnessy, D. A.: Development of a ²¹²Pb and ²¹²Bi generator for homolog studies of flerovium and moscovium. J. Radioanal. Nucl. Chem. 317, 473 (2018).10.1007/s10967-018-5848-7Suche in Google Scholar

55. Hassfjell, S., Brechbiel, M. W.: The development of the α-particle ²¹²Bi and ²¹³Bi and their decay chain related radionuclides, for therapeutic applications. Chem. Rev. 101, 2019 (2001).10.1021/cr000118ySuche in Google Scholar

56. Ruegg, C. L., Anderson-Berg, W. T., Brechbiel, M. W., Mirzadeh, S., Gansow, O. A., Strand, M.: Improved in vivo stability and tumor targeting of bismuth-labeled antibody. Cancer Res. 50, 4221 (1990).Suche in Google Scholar

57. Junghans, R. P., Brechbiel, M. W., Mirzadeh, S., Raubitschek, A. A., Gansow, O. A., Waldmann, T. A.: Pharmacokinetics and bioactivity of 1,4,7,10-tetra-azacylododecane tetraacetic acid (DOTA)-bismuth-conjugated anti-tac antibody for α-emitter (²¹²Bi) therapy. Cancer Res. 53, 5683 (1993).Suche in Google Scholar

58. Kumar, K., Magerstädt, M., Gansow, O. A.: Lead(II) and bismuth(III) complexes of the polyazacycloalkane-N-acetic acids nota, dota and teta. J. Chem. Soc. Chem. Commun. 3, 145 (1989).10.1039/C39890000145Suche in Google Scholar

59. Bartos, B., Lyczko, K., Kasperek, A., Krajewski, S., Bilewicz, A.: Search of ligands suitable for ²¹²Pb/²¹²Bi in vivo generators. J. Radioanal. Nucl. Chem. 295, 205 (2013).10.1007/s10967-012-2238-4Suche in Google Scholar

60. Mirzadeh, S., Kumar, K., Gansow, O. A.: The chemical fate of ²¹²Bi-DOTA formed by β⁻ decay of ²¹²Pb(DOTA)²⁻. Radiochim. Acta 60, 1 (1993).10.1524/ract.1993.60.1.1Suche in Google Scholar

61. Chappell, L. L., Dadachova, K., Milenic, D. E., Garmestani, K., Wu, C., Brechbiel, M. W.: Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes ²⁰³Pb and ²¹²Pb. Nucl. Med. Biol. 27, 93 (2000).10.1016/S0969-8051(99)00086-4Suche in Google Scholar

62. Confino, H., Hochman, I., Efrati, M., Schmidt, M., Umansky, V., Kelson, I., Keisari, Y.: Tumor ablation by intratumoral Ra-224-loaded wires induces anti-tumor immunity against experimental metastatic tumors. Cancer Immunol. Immunother. 64, 191 (2015).10.1007/s00262-014-1626-8Suche in Google Scholar PubMed

63. Yong, K. J., Milenic, D. E., Baidoo, K. E., Brechbiel, M. W.: Cell killing mechanisms and impact on gene expression by gemcitabine and ²¹²Pb-trastuzumab treatment in a disseminated i.p. tumor model. PLoS One 11, e0159904 (2016).10.1371/journal.pone.0159904Suche in Google Scholar PubMed PubMed Central

64. Milenic, D. E., Baidoo, K. E., Kim, Y. S., Brechbiel, M. W.: Evaluation of cetuximab as a candidate for targeted alpha-particle radiation therapy of HER1-positive disseminated intraperitoneal disease. MAbs 7, 255 (2015).10.4161/19420862.2014.985160Suche in Google Scholar PubMed PubMed Central

65. Milenic, D. E., Baidoo, K. E., Brechbiel, M. W.: Bench to bedside: stability studies of GMP produced trastuzumab-TCMC in support of a clinical trial. Pharmaceuticals (Basel) 8, 435 (2015).10.3390/ph8030435Suche in Google Scholar PubMed PubMed Central

66. Meredith, R. F., Torgue, J. J., Rozgaja, T. A., Banaga, E. P., Bunch, P. W., Alvarez, R. D., Straughn, J. M., Jr., Dobelbower, M. C., Lowy, A. M.: Safety and outcome measures of first-in-human intraperitoneal alpha radioimmunotherapy with ²¹²Pb-TCMC-trastuzumab. Am. J. Clin. Oncol. 41, 716 (2018).10.1097/COC.0000000000000353Suche in Google Scholar PubMed PubMed Central

67. Kasten, B. B., Arend, R. C., Katre, A. A., Kim, H., Fan, J., Ferrone, S., Zinn, K. R., Buchsbaum, D. J.: B7-H3-targeted ²¹²Pb radioimmunotherapy of ovarian cancer in preclinical models. Nucl. Med. Biol. 47, 23 (2017).10.1016/j.nucmedbio.2017.01.003Suche in Google Scholar PubMed PubMed Central

68. Kasten, B. B., Gangrade, A., Kim, H., Fan, J., Ferrone, S., Ferrone, C. R., Zinn, K. R., Buchsbaum, D. J.: ²¹²Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models. Nucl. Med. Biol. 58, 67 (2018).10.1016/j.nucmedbio.2017.12.004Suche in Google Scholar PubMed PubMed Central

69. Milenic, D. E., Kim, Y. S., Baidoo, K. E., Wong, K. J., Barkley, R., Delgado, J., Brechbiel, M. W.: Exploration of a F(ab′)₂ fragment as the targeting agent of alpha-radiation therapy: a comparison of the therapeutic benefit of intraperitoneal and intravenous administered radioimmunotherapy. Cancer Biother. Radio. 33, 182 (2018).10.1089/cbr.2018.2434Suche in Google Scholar

70. Morgenstern, A., Bruchertseifer, F., Apostolidis, C.: Bismuth-213 and actinium-225 generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotope. Curr. Radiopharm. 5, 221 (2012).10.2174/1874471011205030221Suche in Google Scholar PubMed

71. Hogle, S., Boll, R. A., Murphy, K., Denton, D., Owens, A., Haverlock, T. J., Garland, M., Mirzadeh, S.: Reactor production of thorium-229. Appl. Radiat. Isotopes 114, 19 (2016).10.1016/j.apradiso.2016.05.002Suche in Google Scholar PubMed

72. Kuznetsov, R. A., Butkalyuk, P. S., Tarasov, V. A., Baranov, A. Y., Butkalyuk, I. L., Romanov, E. G., Kypriyanov, V. N., Kazakova, E. V.: Yields of activation products in ²²⁶Ra irradiation in the high-flux SM reactor. Radiochemistry 54, 383 (2012).10.1134/S1066362212040121Suche in Google Scholar

73. Engle, J. W.: The Production of Ac-225. Curr. Radiopharm. 11, 173 (2018).10.2174/1874471011666180418141357Suche in Google Scholar PubMed

74. Engle, J. W., Weidner, J. W., Ballard, B. D., Fassbender, M. E., Hudston, L. A., Jackman, K. R., Dry, D. E., Wolfsberg, L. E., Bitteker, L. J., Ullmann, J. L., Gulley, M. S., Pillai, C., Goff, G., Birnbaum, E. R., John, K. D., Mashnik, S. G., NortierJohn, F. M., Weidner, W., Ballard, B. D., Fassbender, M. E., Hudston, L. A., Jackman, K. R., Dry, D. E., Wolfsberg, L. E., Bitteker, L. J., Ullmann, J. L., Gulley, M. S., Pillai, C., Goff, G., Birnbaum, E. R., John, K. D., Mashnik, S. G., Nortier, F. M.: Ac, La, and Ce radioimpurities in ²²⁵Ac produced in 40–200 MeV proton irradiations of thorium. Radiochim. Acta 102, 569 (2014).10.1515/ract-2013-2179Suche in Google Scholar

75. Qaim, S. M.: Nuclear data for medical radionuclides. J. Radioanal. Nucl. Chem. 305, 233 (2015).10.1007/s10967-014-3923-2Suche in Google Scholar

76. Zielinska, B., Apostolidis, C., Bruchertseifer, F., Morgenstern, A.: An improved method for the production of Ac-225/Bi-213 from Th-229 for targeted alpha therapy. Solvent Extr. Ion Exc. 25, 339 (2007).10.1080/07366290701285108Suche in Google Scholar

77. Filosofov, D. V., Rakhimov, A. V., Bozhikov, G. A., Karaivanov, D. V., Lebedev, N. A., Norseev, Y. V., Sadikov, I. I.: Isolation of radionuclides from thorium targets irradiated with 300-MeV protons. Radiochemistry 55, 410 (2013).10.1134/S1066362213040127Suche in Google Scholar

78. Mastren, T., et al.: Simultaneous separation of actinium and radium isotopes from a proton irradiated thorium matrix. Sci. Rep. 7, 8216 (2017).10.1038/s41598-017-08506-9Suche in Google Scholar

79. Radchenko, V., Mastren, T., Meyer, C. A. L., Ivanov, A. S., Bryantsev, V. S., Copping, R., Denton, D., Engle, J. W., Griswold, J. R., Murphy, K., Wilson, J. J., Owens, A., Wyant, L., Birnbaum, E. R., Fitzsimmons, J., Medvedev, D., Cutler, C. S., Mausner, L. F., Nortier, M. F., John, K. D., Mirzadeh, S., Fassbender, M. E.: Radiometric evaluation of diglycolamide resins for the chromatographic separation of actinium from fission product lanthanides. Talanta 175, 318 (2017).10.1016/j.talanta.2017.07.057Suche in Google Scholar

80. Bray, L. A., Tingey, J. M., DesChane, J. R., Egorov, O. B., Tenforde, T. S., Wilbur, D. S., Hamlin, D. K., Pathare, P. M.: Development of a unique bismuth (Bi-213) automated generator for use in cancer therapy. Ind. Eng. Chem. Res. 39, 3189 (2000).10.1021/ie990068rSuche in Google Scholar

81. Guseva, L. I., Dogadkin, N. N.: Development of a tandem generator system ²²⁹Th/²²⁵Ac/²¹³Bi for repeated production of short-lived α-emitting radionuclides. Radiochemistry 51, 169 (2009).10.1134/S1066362209020131Suche in Google Scholar

82. Khalkin, V. A., Tsoupka-Sitnikoz, V. V., Zaitseva, N. G.: Radionuclides for radiotherapy. Actinium-225: properties, preparation, application. Radiochemistry 39, 483 (1997).Suche in Google Scholar

83. Ferrier, M. G., Stein, B. W., Bone, S. E., Cary, S. K., Ditter, A. S., Kozimor, S. A., Lezama Pacheco, J. S., Mocko, V., Seidler, G. T.: The coordination chemistry of Cm^III, Am^III, and Ac^III in nitrate solutions: an actinide L₃-edge EXAFS study. Chem. Sci. 9, 7078 (2018).10.1039/C8SC02270DSuche in Google Scholar

84. Robertson, A. K. H., Ramogida, C. F., Schaffer, P., Radchenko, V.: Development of ²²⁵Ac radiopharmaceuticals: TRIUMF perspectives and experiences. Curr. Radiopharm. 11, 156 (2018).10.2174/1874471011666180416161908Suche in Google Scholar

85. McDevitt, M. R., Ma, D., Simon, J., Frank, R. K., Scheinberg, D. A.: Design and synthesis of ²²⁵Ac radioimmunopharmaceuticals. Appl. Radiat. Isotopes 57, 841 (2002).10.1016/S0969-8043(02)00167-7Suche in Google Scholar

86. Jaggi, J. S., Kappel, B. J., McDevitt, M. R., Sgouros, G., Flombaum, C. D., Cabassa, C., Scheinberg, D. A.: Efforts to control the errant products of a targeted in vivo generator. Cancer Res. 65, 4888 (2005).10.1158/0008-5472.CAN-04-3096Suche in Google Scholar PubMed

87. Kratochwil, C., Bruchertseifer, F., Giesel, F. L., Weis, M., Verburg, F. A., Mottaghy, F., Kopka, K., Apostolidis, C., Haberkorn, U., Morgenstern, A.: ²²⁵Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy of metastatic castration-resistant prostate cancer. J. Nucl. Med. 57, 1941 (2016).10.2967/jnumed.116.178673Suche in Google Scholar PubMed

88. Chappell, L. L., Deal, K. A., Dadachova, E., Brechbiel, M. W.: Synthesis, conjugation, and radiolabeling of a novel bifunctional chelating agent for ²²⁵Ac radioimmunotherapy applications. Bioconj. Chem. 11, 510 (2000).10.1021/bc990153fSuche in Google Scholar PubMed

89. Thiele, N. A., et al.: An eighteen-membered macrocyclic ligand for actinium-225 targeted alpha therapy. Angew. Chem. Int. Edit. 56, 14712 (2017).10.1002/anie.201709532Suche in Google Scholar PubMed

90. Morgenstern, A. F., Bruchertseifer, F., Apostolidis, C.: Targeted alpha therapy with ²¹³Bi. Curr. Radiopharm. 4, 295 (2011).10.2174/1874471011104040295Suche in Google Scholar PubMed

91. Morgenstern, A., Apostolidis, C., Kratochwil, C., Sathekge, M., Krolicki, L., Bruchertseifer, F.: An overview of targeted alpha therapy with ²²⁵actinium and ²¹³bismuth. Curr. Radiopharm. 11, 200 (2018).10.2174/1874471011666180502104524Suche in Google Scholar PubMed PubMed Central

92. Park, S. I., Shenoi, J., Pagel, J. M., Hamlin, D. K., Wilbur, D. S., Orgun, N., Kenoyer, A. L., Frayo, S., Axtman, A., Bäck, T., Lin, Y., Fisher, D. R., Gopal, A. K., Green, D. J., Press, O. W.: Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. Blood 116, 4231 (2010).10.1182/blood-2010-05-282327Suche in Google Scholar PubMed PubMed Central

93. Wilson, J. J., Ferrier, M., Radchenko, V., Maassen, J. R., Engle, J. W., Batista, E. R., Martin, R. L., Nortier, F. M., Fassbender, M. E., John, K. D., Birnbaum, E. R.: Evaluation of nitrogen-rich macrocyclic ligands for the chelation of therapeutic bismuth radioisotopes. Nucl. Med. Biol. 42, 428 (2015).10.1016/j.nucmedbio.2014.12.007Suche in Google Scholar PubMed

94. Simecek, J., Hermann, P., Seidl, C., Bruchertseifer, F., Morgenstern, A., Wester, H. J., Notni, J.: Efficient formation of inert Bi-213 chelates by tetraphosphorus acid analogues of DOTA: towards improved alpha-therapeutics. EJNMMI Res. 8, 78 (2018).10.1186/s13550-018-0431-3Suche in Google Scholar PubMed PubMed Central

95. Sathekge, M., Knoesen, O., Meckel, M., Modiselle, M., Vorster, M., Marx, S.: ²¹³Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer. Eur. J. Nucl. Med. Mol. I. 44, 1099 (2017).10.1007/s00259-017-3657-9Suche in Google Scholar PubMed PubMed Central

96. Krolicki, L., et al.: Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with ²¹³Bi-substance P analogue. Eur. J. Nucl. Med. Mol. I. 45, 1636 (2018).10.1007/s00259-018-4015-2Suche in Google Scholar PubMed PubMed Central

97. Kratochwil, C., Bruchertseifer, F., Rathke, H., Hohenfellner, M., Giesel, F. L., Haberkorn, U., Morgenstern, A.: Targeted α-therapy of metastatic castration-resistant prostate cancer with ²²⁵Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J. Nucl. Med. 59, 795 (2018).10.2967/jnumed.117.203539Suche in Google Scholar PubMed

98. Kratochwil, C., Schmidt, K., Afshar-Oromieh, A., Bruchertseifer, F., Rathke, H., Morgenstern, A., Haberkorn, U., Giesel, F. L.: Targeted alpha therapy of mCRPC: dosimetry estimate of ²¹³Bismuth-PSMA-617. Eur. J. Nucl. Med. Mol. I. 45, 31 (2018).10.1007/s00259-017-3817-ySuche in Google Scholar PubMed PubMed Central

99. Raja, C., Graham, P., Rizvi, S., Song, E., Goldsmith, H., Thompson, J., Bosserhoff, A., Morgenstern, A., Apostolidis, C., Kearsley, J., Reisfeld, R., Allen, B. J.: Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma. Cancer Biol. Ther. 6, 846 (2007).10.4161/cbt.6.6.4089Suche in Google Scholar PubMed

100. Allen, B. J., Singla, A. A., Rizvi, S. M., Graham, P., Bruchertseifer, F., Apostolidis, C., Morgenstern, A.: Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma. Immunotherapy. Immunotherapy 3, 1041 (2011).10.2217/imt.11.97Suche in Google Scholar PubMed

101. Allen, B. J., Raja, C., Rizvi, S., Li, Y., Tsui, W., Graham, P., Thompson, J., Reisfeld, R., Kearsley, J., Morgenstern, A., Apostolidis, C.: Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol. Ther. 4, 1318 (2005).10.4161/cbt.4.12.2251Suche in Google Scholar PubMed

102. Cordier, D., Forrer, F., Bruchertseifer, F., Morgenstern, A., Apostolidis, C., Good, S., Muller-Brand, J., Macke, H., Reubi, J. C., Merlo, A.: Targeted alpha-radionuclide therapy of functionally critically located gliomas with ²¹³Bi-DOTA-[Thi⁸, Met(O₂)¹¹]-substance P: a pilot trial. Eur. J. Nucl. Med. Mol. I. 37, 1335 (2010).10.1007/s00259-010-1385-5Suche in Google Scholar PubMed

103. Kratochwil, C., Giesel, F. L., Bruchertseifer, F., Mier, W., Apostolidis, C., Boll, R., Murphy, K., Haberkorn, U., Morgenstern, A.: ²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur. J. Nucl. Med. Mol. I. 41, 2106 (2014).10.1007/s00259-014-2857-9Suche in Google Scholar PubMed PubMed Central

104. Pruszynski, M., D’Huyvetter, M., Bruchertseifer, F., Morgenstern, A., Lahoutte, T.: Evaluation of an anti-HER2 nanobody labeled with ²²⁵Ac for targeted alpha-particle therapy of cancer. Mol. Pharm. 15, 1457 (2018).10.1021/acs.molpharmaceut.7b00985Suche in Google Scholar PubMed

105. McDevitt, M. R., Thorek, D. L. J., Hashimoto, T., Gondo, T., Veach, D. R., Sharma, S. K., Kalidindi, T. M., Abou, D. S., Watson, P. A., Beattie, B. J., Timmermand, O. V., Strand, S. E., Lewis, J. S., Scardino, P. T., Scher, H. I., Lilja, H., Larson, S. M., Ulmert, D.: Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nat. Commun. 9, 1629 (2018).10.1038/s41467-018-04107-wSuche in Google Scholar PubMed PubMed Central

106. Majkowska-Pilip, A., Rius, M., Bruchertseifer, F., Apostolidis, C., Weis, M., Bonelli, M., Laurenza, M., Krolicki, L., Morgenstern, A.: In vitro evaluation of ²²⁵Ac-DOTA-substance P for targeted alpha therapy of glioblastoma multiforme. Chem. Biol. Drug Des. 92, 1344 (2018).10.1111/cbdd.13199Suche in Google Scholar PubMed

107. Jurcic, J. G.: Clinical studies with bismuth-213 and actinium-225 for hematologic malignancies. Curr. Radiopharm. 11, 192 (2018).10.2174/1874471011666180525102814Suche in Google Scholar PubMed

108. Henriksen, G., Hoff, P., Alstad, J., Larsen, R. H.: ²²³Ra for endoradiotherapeutic applications prepared from an immobilized ²²⁷Ac/²²⁷Th source. Radiochim. Acta 89, 661 (2001).10.1524/ract.2001.89.10.661Suche in Google Scholar

109. Soderquist, C. Z., McNamara, B. K., Fisher, D. R.: Production of high-purity radium-223 from legacy actinium-beryllium neutron sources. Curr. Radiopharm. 5, 244 (2012).10.2174/1874471011205030244Suche in Google Scholar PubMed

110. Zhuikov, B. L., Kalmykov, S. N., Ermolaev, S. V., Aliev, R. A., Kokhanyuk, V. M., Matushko, V. L., Tananaev, I. G., Myasoedov, B. F.: Production of ²²⁵Ac and ²²³Ra by irradiation of Th with accelerated protons. Radiochemistry 53, 73 (2011).10.1134/S1066362211010103Suche in Google Scholar

111. Weidner, J. W., Mashnik, S. G., John, K. D., Hemez, F., Ballard, B., Bach, H., Birnbaum, E. R., Bitteker, L. J., Couture, A., Dry, D., Fassbender, M. E., Gulley, M. S., Jackman, K. R., Ullmann, J. L., Wolfsberg, L. E., Nortier, F. M.: Proton-induced cross sections relevant to production of ²²⁵Ac and ²²³Ra in natural thorium targets below 200 MeV. Appl. Radiat. Isotopes 70, 2602 (2012).10.1016/j.apradiso.2012.07.006Suche in Google Scholar PubMed

112. Ivanov, P. I., Collins, S. M., van Es, E. M., Garcia-Miranda, M., Jerome, S. M., Russell, B. C.: Evaluation of the separation and purification of ²²⁷Th from its decay progeny by anion exchange and extraction chromatography. Appl. Radiat. Isotopes 124, 100 (2017).10.1016/j.apradiso.2017.03.020Suche in Google Scholar PubMed

113. Vasiliev, A. N., Ostapenko, V. S., Lapshina, E. V., Ermolaev, S. V., Danilov, S. S., Zhuikov, B. L., Kalmykov, S. N.: Recovery of Ra-223 from natural thorium irradiated by protons. Radiochim. Acta 104, 539 (2016).10.1515/ract-2015-2549Suche in Google Scholar

114. Guseva, L. I., Tikhomirova, G. S., Dogadkin, N. N.: Anion-exchange separation of radium from alkaline-earth metals and actinides in aqueous-methanol solutions of HNO₃. ²²⁷Ac-²²³Ra generator. Radiochemistry 46, 58 (2004).10.1023/B:RACH.0000024637.39523.e4Suche in Google Scholar

115. Larsen, R. H., Borrebaek, J., Dahle, J., Melhus, K. B., Krogh, C., Valan, M. H., Bruland, O. S.: Preparation of TH²²⁷-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability. Cancer Biother. Radiopharm. 22, 431 (2007).10.1089/cbr.2006.321Suche in Google Scholar PubMed

116. Heyerdahl, H., Abbas, N., Brevik, E. M., Mollatt, C., Dahle, J.: Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting ²²⁷Th-DOTA-p-benzyl-trastuzumab. PLoS One 7, e42345 (2012).10.1371/journal.pone.0042345Suche in Google Scholar PubMed PubMed Central

117. Frenvik, J. O., Dyrstad, K., Kristensen, S., Ryan, O. B.: Development of separation technology for the removal of radium-223 from targeted thorium conjugate formulations. Part II: purification of targeted thorium conjugates on cation exchange columns. Drug Dev Ind Pharm 43, 1440 (2017).10.1080/03639045.2017.1318906Suche in Google Scholar PubMed

118. Ramdahl, T., Bonge-Hansen, H. T., Ryan, O. B., Larsen, S., Herstad, G., Sandberg, M., Bjerke, R. M., Grant, D., Brevik, E. M., Cuthbertson, A. S.: An efficient chelator for complexation of thorium-227. Bioorg. Med. Chem. Lett. 26, 4318 (2016).10.1016/j.bmcl.2016.07.034Suche in Google Scholar PubMed

119. Hagemann, U. B., Mihaylova, D., Uran, S. R., Borrebaek, J., Grant, D., Bjerke, R. M., Karlsson, J., Cuthbertson, A. S.: Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in in vitro and in vivo models of renal cell carcinoma. Oncotarget 8, 56311 (2017).10.18632/oncotarget.16910Suche in Google Scholar PubMed PubMed Central

120. Captain, I., Deblonde, G. J., Rupert, P. B., An, D. D., Illy, M. C., Rostan, E., Ralston, C. Y., Strong, R. K., Abergel, R. J.: Engineered recognition of tetravalent zirconium and thorium by chelator-protein systems: toward flexible radiotherapy and imaging platforms. Inorg. Chem. 55, 11930 (2016).10.1021/acs.inorgchem.6b02041Suche in Google Scholar PubMed

121. Gott, M., Steinbach, J., Mamat, C.: The radiochemical and radiopharmaceutical applications of radium. Open Chem. 14, 118 (2016).10.1515/chem-2016-0011Suche in Google Scholar

122. Henriksen, G., Schoultz, B. W., Michaelsen, T. E., Bruland, O. S., Larsen, R. H.: Sterically stabilized liposomes as a carrier for α-emitting radium and actinium radionuclides. Nucl. Med. Biol. 31, 441 (2004).10.1016/j.nucmedbio.2003.11.004Suche in Google Scholar PubMed

123. Dahle, J., Borrebaek, J., Jonasdottir, T. J., Hjelmerud, A. K., Melhus, K. B., Bruland, O. S., Press, O. W., Larsen, R. H.: Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate. Blood 110, 2049 (2007).10.1182/blood-2007-01-066803Suche in Google Scholar PubMed

124. Hagemann, U. B., Wickstroem, K., Wang, E., Shea, A. O., Sponheim, K., Karlsson, J., Bjerke, R. M., Ryan, O. B., Cuthbertson, A. S.: In vitro and in vivo efficacy of a novel CD33-targeted thorium-227 conjugate for the treatment of acute myeloid leukemia. Mol. Cancer Ther. 15, 2422 (2016).10.1158/1535-7163.MCT-16-0251Suche in Google Scholar PubMed

125. Nilsson, S.: Radionuclide therapies in prostate cancer: integrating radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer. Curr. Oncol. Rep. 18, 14 (2016).10.1007/s11912-015-0495-4Suche in Google Scholar PubMed PubMed Central

126. Bruland, O. S., Jonasdottir, T. J., Fisher, D. R., Larsen, R. H.: Radium-223: from radiochemical development to clinical applications in targeted cancer therapy. Curr. Radiopharm. 1, 203 (2008).10.2174/1874471010801030203Suche in Google Scholar

127. Liepe, K., Shinto, A.: From palliative therapy to prolongation of survival: ²²³RaCl₂ in the treatment of bone metastases. Ther. Adv. Med. Oncol. 8, 294 (2016).10.1177/1758834016640494Suche in Google Scholar PubMed PubMed Central

128. Kluetz, P. G., Pierce, W., Maher, V. E., Zhang, H., Tang, S., Song, P., Liu, Q., Haber, M. T., Leutzinger, E. E., Al-Hakim, A., Chen, W., Palmby, T., Alebachew, E., Sridhara, R., Ibrahim, A., Justice, R., Pazdur, R.: Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary. Clin. Cancer Res. 20, 9 (2014).10.1158/1078-0432.CCR-13-2665Suche in Google Scholar PubMed

129. Florimonte, L., Dellavedova, L., Maffioli, L. S.: Radium-223 dichloride in clinical practice: a review. Eur. J. Nucl. Med. Mol. I. 43, 1896 (2016).10.1007/s00259-016-3386-5Suche in Google Scholar

130. Parker, C., Heidenreich, A., Nilsson, S., Shore, N.: Current approaches to incorporation of radium-223 in clinical practice. Prostate Cancer Prostatic Dis. 21, 37 (2018).10.1038/s41391-017-0020-ySuche in Google Scholar

131. Saad, F., et al.: Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol. 17, 1306 (2016).10.1016/S1470-2045(16)30173-5Suche in Google Scholar

132. Radchenko, V., Engle, J. W., Wilson, J. J., Maassen, J. R., Nortier, M. F., Birnbaum, E. R., John, K. D., Fassbender, M. E.: Formation cross-sections and chromatographic separation of protactinium isotopes formed in proton-irradiated thorium metal. Radiochim. Acta 104, 291 (2016).10.1515/ract-2015-2486Suche in Google Scholar

133. Morgenstern, A., Lebeda, O., Stursa, J., Bruchertseifer, F., Capote, R., McGinley, J., Rasmussen, G., Sin, M., Zielinska, B., Apostolidis, C.: Production of U-230/Th-226 for targeted alpha therapy via proton irradiation of Pa-231. Anal. Chem. 80, 8763 (2008).10.1021/ac801304cSuche in Google Scholar PubMed

134. Morgenstern, A., Apostolidis, C., Bruchertseifer, F., Capote, R., Gouder, T., Simonelli, F., Sin, M., Abbas, K.: Cross-sections of the reaction Th-232(p,3n)Pa-230 for reaction of U-230 production for targeted alpha therapy. Appl. Radiat. Isotopes 66, 1275 (2008).10.1016/j.apradiso.2008.02.066Suche in Google Scholar PubMed

135. Duchemin, C., Guertin, A., Haddad, F., Michel, N., Metivier, V.: ²³²Th(d,4n)²³⁰Pa cross-section measurements at ARRONAX facility for the production of ²³⁰U. Nucl. Med. Biol. 41(Suppl), e19 (2014).10.1016/j.nucmedbio.2013.12.011Suche in Google Scholar PubMed

136. Dybczynski, R. S., Pyszynska, M., Chajduk, E.: A novel method for the separation of uranium, protactinium and thorium by cation exchange chromatography. In: J. Michalik, W. Smulek, E. Godlewska-Para, (Eds.), Warsaw, (2010), p. 70.Suche in Google Scholar

137. Mastren, T., Stein, B. W., Parker, T. G., Radchenko, V., Copping, R., Owens, A., Wyant, L. E., Brugh, M., Kozimor, S. A., Nortier, F. M., Birnbaum, E. R., John, K. D., Fassbender, M. E.: Separation of protactinium employing sulfur-based extraction chromatographic resins. Anal. Chem. 90, 7012 (2018).10.1021/acs.analchem.8b01380Suche in Google Scholar PubMed

138. Müller, C., Domnanich, K. A., Umbricht, C. A., Van der Meulen, N. P.: Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application. Brit. J. Radiol. 91, 20180074 (2018).10.1259/bjr.20180074Suche in Google Scholar PubMed PubMed Central

139. Allen, B. J.: Targeted alpha therapy: evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer. Australas. Radiol. 43, 480 (1999).10.1046/j.1440-1673.1999.00717.xSuche in Google Scholar PubMed

140. Beyer, G. J., Comor, J. J., Dakovic, M., Soloviev, D., Tamburella, C., Hagebø, E., Allan, B., Dmitriev, S. N., Zaitseva, N. G.: Production routes of the alpha emitting ¹⁴⁹Tb for medical application. Radiochim. Acta 90, 247 (2002).10.1524/ract.2002.90.5_2002.247Suche in Google Scholar

141. Zaitseva, N. G., Dmitriev, S. N., Maslov, O. D., Molokanova, L. G., Starodub, G. Y., Shishkin, S. V., Shishkina, T. V., Beyer, G. J.: Terbium-149 for nuclear medicine. The production of ¹⁴⁹Tb via heavy ions induced nuclear reactions Czech. J. Phys. 53, A455 (2003).10.1007/s10582-003-0058-zSuche in Google Scholar

142. Beyer, G. J., Miederer, M., Vranjes-Duric, S., Comor, J. J., Künzi, G., Hartley, O., Senekowitsch-Schmidtke, R., Soloviev, D., Buchegger, F.: Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using ¹⁴⁹Tb-rituximab. Eur. J. Nucl. Med. Mol. I. 31, 547 (2004).10.1007/s00259-003-1413-9Suche in Google Scholar

143. Müller, C., Zhernosekov, K., Koster, U., Johnston, K., Dorrer, H., Hohn, A., van der Walt, N. T., Turler, A., Schibli, R.: A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for alpha- and beta-radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative. J. Nucl. Med. 53, 1951 (2012).10.2967/jnumed.112.107540Suche in Google Scholar

144. Kulyukhin, S. A., Auerman, L. N., Novichenko, V. L., Mikheev, N. B., Rumer, I. A., Kamenskaya, A. N., Goncharov, L. A., Smirnov, A. I.: Production of microgram quantities of einsteinium-253 by the reactor irradiation of californium. Inorg. Chim. Acta 110, 25 (1985).10.1016/S0020-1693(00)81347-XSuche in Google Scholar

145. Baybarz, R. D.: Dissociation constants of the transplutonium element chelates of diethylenepentaacetic acid (DTPA) and the application of DTPA chelates to solvent extraction separations of transplutonium elements from the lanthanide elements. J. Inorg. Nucl. Chem. 27, 1831 (1965).10.1016/0022-1902(65)80327-XSuche in Google Scholar